Teriparatide Injection

What Is It?

Chemistry & Mechanism of Action

• PTH is a single polypeptide of 84 amino acids (~9500 Da). Residues 1-27 are required for optimal receptor binding and activity.
• Teriparatide acts on PTH-1 receptor (PTHR), a G protein-coupled receptor.
• Intermittent (once-daily) administration stimulates osteoblasts and promotes bone growth - in contrast to continuous PTH elevation (as in primary hyperparathyroidism) which causes bone demineralization.
• Both bone formation and resorption markers increase, but formation predominates with intermittent dosing, leading to net anabolic effect.

Goodman & Gilman's, Katzung's Basic and Clinical Pharmacology 16E

Pharmacokinetics (ADME)

Goodman & Gilman's

Dose & Administration

• Dose: 20 µg once daily by subcutaneous injection
• Injection site: Thigh or abdomen (rotate sites)
• Same time each day (giving at bedtime can help minimize side effects like dizziness)
• Supplied as a pre-filled pen device
• Maximum lifetime duration: 24 months (cumulative; not per course)

Approved Indications

1. Postmenopausal osteoporosis at high risk for fracture
2. Men with primary or hypogonadal osteoporosis
3. Patients who failed or are intolerant to other osteoporosis therapy (glucocorticoid-induced osteoporosis)
4. Severe osteoporosis with history of osteoporotic fracture or multiple risk factors

Goodman & Gilman's, Goldman-Cecil Medicine

Efficacy - Fracture Reduction

• Vertebral fractures: Reduced by ~65-69% (relative risk reduction)
• Nonvertebral fractures: Reduced by ~50%
• Lumbar spine BMD: Increases by ~10% over 2 years
• Vs risedronate: Teriparatide reduced subsequent vertebral fractures by ~50% in women with painful acute osteoporotic vertebral fractures

Harrison's Principles of Internal Medicine 22E (2025)

Sequencing & Combination Therapy

Goldman-Cecil Medicine, Harrison's 22E

Adverse Effects

Contraindications (Osteosarcoma Risk Factors)

• Paget's disease of bone
• Unexplained elevation of alkaline phosphatase
• Open epiphyses (pediatric patients, young adults)
• Prior skeletal radiation therapy
• Bone metastases or skeletal malignancy
• Pre-existing hypercalcemia

Recent Evidence (2024-2026)

• Li et al., 2024 - Arch Osteoporos (PMID 39312040): Systematic review/meta-analysis comparing teriparatide vs bisphosphonates in treatment-naive patients - confirmed teriparatide superiority for BMD and fracture outcomes.
• Beaudart et al., 2025 - Osteoporos Int (PMID 40047881): Network meta-analysis of PTH1 receptor agonists (teriparatide, abaloparatide) for fracture risk - supports use in high-risk patients.
• Nayak & Greenspan, 2026 - Osteoporos Int (PMID 41105226): Systematic review of sequential treatment strategies - confirms the importance of following teriparatide with an antiresorptive to maintain benefits.

Key Clinical Points (Summary)

1. Only anabolic (bone-forming) agent in widespread use for osteoporosis
2. 20 µg SC once daily, max 24 months lifetime use
3. Must be followed by antiresorptive to preserve BMD gains
4. Do not use after denosumab (BMD loss occurs)
5. Black-box warning for osteosarcoma but no proven causal link in humans
6. Side effects mild and usually remit; giving at bedtime reduces dizziness
7. Generic/biosimilar versions (same dose) now available

Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics, Goldman-Cecil Medicine, Harrison's Principles of Internal Medicine 22E (2025), Katzung's Basic and Clinical Pharmacology 16E

Teriparatide Duration Limits: What 2024-2026 Guidelines Say

The Core Story: A Major Regulatory Shift in 2020

• In 2020, the FDA updated the teriparatide label based on large real-world observational studies (using pharmacy claims linked to cancer registries), which showed no increase in osteosarcoma risk in teriparatide-treated patients compared to untreated populations or expected background incidence.
• The black-box warning was removed and the 2-year lifetime limitation was revised - it was no longer presented as an absolute hard cap tied to osteosarcoma fear.
• Only 3 cases of osteosarcoma were identified in over 1 million patients treated, consistent with the expected background incidence.
• Key data point: 2 years represents ~2-3% of a human lifespan, vs ~90% of a rat's lifespan - making rat data non-translatable.

Krege et al., JBMR Plus 2022 (PMID 36111201) - the definitive account of this label update process.

Current Regulatory Position (Post-2020, Confirmed Through 2024-2026)

BC PAD Service, August 2024 update; PubChem FDA label summary

2024-2026 Society Guidelines - What They Recommend

1. European Calcified Tissue Society (ECTS) - 2024

• Very high fracture risk (age ≥70 with recent hip/pelvic fracture or severe vertebral fracture): teriparatide as first-line treatment
• Explicitly mandates sequential therapy after teriparatide (transition to antiresorptive)
• Does not set a different duration limit; defers to standard 24-month course with mandatory follow-on

2. European Guidelines Comparison Review - 2024

"There was agreement that patients at high or very high risk of fracture or with severe osteoporosis should receive anabolic agents first, followed by antiresorptive drugs."

• All European guidelines align on anabolic-first (teriparatide or romosozumab) for high/very high risk, sequential treatment mandatory
• No guideline extended the duration cap beyond 24 months, but none re-imposed the osteosarcoma black-box restriction either

3. 2025 Singapore Consensus Statements (Asia-Pacific)

"Teriparatide may be extended beyond 24 months when clinically justified, with subsequent antiresorptive consolidation likewise imperative."

• Explicitly acknowledges that extension beyond 24 months is permissible in very high-risk patients
• References Asia-Pacific and East Asian real-world data supporting this

4. American College of Physicians (ACP) - 2023 (Most Recent ACP Guideline)

• Recommends teriparatide followed by bisphosphonate specifically for women with primary osteoporosis at very high fracture risk
• Supports the anabolic-then-antiresorptive sequence

5. B.C. Provincial Academic Detailing Service - August 2024 Update

• "US FDA 2020 review: evidence no longer supports a warning for osteosarcoma"
• "Health Canada & US FDA: continue beyond 24 months of lifetime exposure only if high risk for fracture"
• "Approved for a maximum of 24 months of use for most people; guidelines recommend subsequent treatment with a bisphosphonate or denosumab"

Summary: The Current Clinical Position (2026)

Recent Supporting Evidence

• Li et al., Arch Osteoporos, 2024 (PMID 39312040) - Meta-analysis confirming teriparatide superiority over bisphosphonates in treatment-naive high-risk patients
• Beaudart et al., Osteoporos Int, 2025 (PMID 40047881) - Network meta-analysis of PTH1R agonists supporting fracture risk reduction
• Nayak & Greenspan, Osteoporos Int, 2026 (PMID 41105226) - Sequential treatment strategies meta-analysis, confirming anabolic-then-antiresorptive is optimal